Travere Therapeutics (TVTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Travere Therapeutics (TVTX) is Neutral.

The composite score behind that read is +0.06, weighing +0.08 of bullish evidence against -0.14 bearish.

Travere Therapeutics last closed at $52.12, +0.15% on the session.

Against the IVW growth benchmark the position is -0.65% over the forecast window.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 53%.

1 graded prediction for TVTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Travere Therapeutics in the 12th percentile on return on equity, where 100 is best.

Travere Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $4.91B.

StockMap tracks Travere Therapeutics as the 53rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Travere Therapeutics ranks 68th of 381 in the group, against a group median of -0.08.